AI Article Synopsis
- Many countries recommend cervical cancer screening start at 25, but premature screening may lead to unnecessary procedures.
- This study analyzed data from 4,297 women under 25 and found that nearly 48.5% had undergone premature screening.
- Women using prescription contraceptives, like birth control pills, were more likely to have premature screenings, especially those who were younger or had multiple sexual partners.
- The findings suggest that the type of contraceptive used can influence the likelihood of undergoing unnecessary early cervical cancer screenings.
Article Abstract
Background: Many countries currently recommend that screening for cervical cancer begin at the age of 25 years. Premature screening (before that age) could lead to unnecessary follow-up examinations and procedures that turn out to be useless. Our objective is to ascertain if the use of particular contraceptive methods are associated with premature screening.
Methods: This cross-sectional study based on the CONSTANCES cohort enabled us to include 4297 women younger than 25 years. The factors associated with premature screening were modeled by logistic regression. Missing data were handled by multiple imputations. The multivariate analyses were adjusted for sex life, social and demographic characteristics, and health status.
Results: Nearly half (48.5%) the women younger than 25 years had already undergone premature screening. Women not using contraceptives (aOR 0.3, 95% CI 0.3-0.5) and those using nonmedicalized contraceptives (condom, spermicide, etc.) (aOR 0.5, 95% CI 0.4-0.6) had premature screening less often than women using birth control pills. Higher risks of premature screening were observed in 20-year-old women (aOR 2.7, 95% CI 2.2-3.3) and in those with more than 5 lifetime partners (aOR 2.5, 95% CI 2.0-3.1), compared respectively with women who were younger and those with 5 or fewer lifetime partners.
Conclusion: Young women using contraceptives that require a doctor's prescription are exposed to premature screening more often than those not using contraception and those with nonmedicalized contraceptives.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993455 | PMC |
| http://dx.doi.org/10.1186/s12889-021-10603-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraventricular Hemorrhage and Survival, Multimorbidity, and Neurodevelopment.
JAMA Netw Open
January 2025
Population Policy and Practice, Great Ormond Street UCL Institute of Child Health, London, United Kingdom.
Importance: Intraventricular hemorrhage (IVH) has proven to be a challenging and enduring complication of prematurity. However, its association with neurodevelopment across the spectrum of IVH severity, independent of prematurity, and in the context of contemporary care remains uncertain.
Objective: To evaluate national trends in IVH diagnosis and the association with survival and neurodevelopmental outcomes at 2 years of age.
Unlabelled: Hemodynamically significant patent ductus arteriosus (hs-PDA) in very low birth weight (VLBW) infants continues to be an issue of research regarding the timing of treatment and which would be the most appropriate drug.
Objective: To assess the outcome of prolonged treatment with paracetamol in the closure of hemodynamically significant patent ductus arteriosus in preterm newborns.
Patients And Method: Retrospective study in VLBW infants with echocardiographic and clinical diagnosis of hs-PDA who received treatment with intravenous paracetamol at 15 mg/kg every 6 hours for 6 days.
Mutation in and a Variant Linked to a Severe Sporadic Infant Dilated Cardiomyopathy Case.
Case Rep Genet
December 2024
Cardiovascular Research Department, Lankenau Institute for Medical Research, Lankenau Hearth Institute, Wynnewood, Pennsylvania 19096, USA.
Structural or electrophysiologic cardiac anomalies may compromise cardiac function, leading to sudden cardiac death (SCD). Genetic screening of families with severe cardiomyopathies underlines the role of genetic variations in cardiac-specific genes. The present study details the clinical and genetic characterization of a malignant dilated cardiomyopathy (DCM) case in a 1-year-old Mexican child who presented a severe left ventricular dilation and dysfunction that led to SCD.
View Article and Find Full Text PDFFirst Report from Saudi Arabia of Trimethylaminuria Caused by a Premature Stop Codon Mutation in the Gene.
Appl Clin Genet
December 2024
Medical Genomics Research Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Background: Trimethylaminuria (TMAU) is a rare recessive genetic disorder with limited global prevalence. To date, there have been no official reports of TMAU cases documented in Saudi Arabia.
Purpose: In this study, we developed a liquid chromatography-mass spectrometry (LC-MS) method for the analysis of trimethylamine (TMA) and Trimethylamine N-Oxide (TMAO) in urine and plasma samples for the first reported case of TMAU in Saudi Arabia.
Knowledge Mapping of Stem Cell Therapy for Premature Ovarian Insufficiency: A Bibliometric Analysis (2000-2023).
Curr Stem Cell Res Ther
December 2024
Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University/Beijing Maternal and Child Health Care Hospital, Beijing, China.
Background: Premature Ovarian Failure (POI), a prevalent gynecological, endocrine disease, significantly impairs the reproductive health of women of childbearing age and presents a formidable challenge to clinicians. Until now, there has been a lack of effective treatments to fundamentally improve ovarian function in patients with POI. Stem cell therapy has emerged as a promising treatment in the field of POI, with notable research progress achieved to date.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!